.Nature Medication, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint asks for addition of patients along with MASLD as well as dimension of liver end results in cardio-- renal-- metabolic trials, when records propose mechanistically plausible benefits as well as medical security-- and also outlines factors to consider for test style and also governing approval.